Skip to main content
QNCX
NASDAQ Life Sciences

Quince Therapeutics' Lead Drug eDSP Fails Pivotal Phase 3 Trial, Halts Development

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.28
Mkt Cap
$177.067M
52W Low
$0.23
52W High
$4.55
52W Position info
22% above low
Off High info
94% below high
Rel. Volume info
17× avg
Market data snapshot near publication time

QNCX sits 22% above its 52-week low of $0.23 on elevated volume (17× avg).

Summary

Quince Therapeutics announced that its lead drug candidate, eDSP, failed to meet primary and key secondary endpoints in its pivotal Phase 3 clinical trial, leading the company to halt development and explore strategic options.


Key Events · Product Development and Regulatory · QNCX

  • Lead Asset Fails Phase 3 Trial

    The pivotal Phase 3 NEAT clinical trial for eDSP in Ataxia-Telangiectasia did not achieve statistical significance for its primary or key secondary endpoints.

  • Cessation of eDSP Development

    Following the trial results, Quince Therapeutics will cease all clinical development of eDSP.

  • Strategic Re-evaluation

    The company intends to preserve cash and explore available options, signaling a significant strategic shift after the failure of its lead program.


Analysis · QNCX · Life Sciences

Quince Therapeutics announced the failure of its lead asset, eDSP, in the pivotal Phase 3 NEAT clinical trial for Ataxia-Telangiectasia. Neither the primary nor key secondary endpoints achieved statistical significance, leading the company to cease all clinical development of eDSP. This outcome is a significant setback, effectively eliminating the company's most advanced pipeline candidate and forcing a strategic re-evaluation. The company's stated intention to "preserve cash and explore available options" suggests a critical juncture, potentially involving a pivot to new assets, a merger, or other significant corporate actions to sustain operations.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, QNCX was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $177.1M. The 52-week trading range was $0.23 to $4.55. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QNCX - Latest Insights

QNCX
Oct 09, 2026, 8:10 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $31.00
Real-time Price: $31.73 info
Change: +$0.730 (+2%) info
Market Cap: $32.271M info
QNCX
Oct 09, 2026, 7:59 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $29.36
Real-time Price: $31.73 info
Change: +$2.37 (+8%) info
Market Cap: $32.271M info
QNCX
Oct 06, 2026, 4:57 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.81
Real-time Price: $31.73 info
Change: +$4.92 (+18%) info
Market Cap: $32.271M info
QNCX
Sep 14, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $28.59
Real-time Price: $31.73 info
Change: +$3.14 (+11%) info
Market Cap: $32.271M info
QNCX
Sep 04, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $30.55
Real-time Price: $31.73 info
Change: +$1.18 (+4%) info
Market Cap: $32.271M info